Bruna M. Silva,1,2 Giovanni F. Gomes,1 Flavio P. Veras,1 Seppe Cambier,3 Gabriel V.L. Silva,1,2 Andreza U. Quadros,1 Diego B. Caetité,1,2 Daniele C. Nascimento,1,2 Camilla M. Silva,1,2 Juliana C. Silva,1 Samara Damasceno,1 Ayda H. Schneider,1 Fabio Beretta,3 Sabrina S. Batah,4 Icaro M.S. Castro,5 Isadora M. Paiva,1 Tamara […]
Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders
Hironori Tsuchiya, Christos Rahiotis, Academic Editor and Nikolaos Gkantidis, Academic EditorDent J (Basel). 2023 Jun; 11(6): 140. Published online 2023 May 25. doi: 10.3390/dj11060140, PMCID: PMC10297082 PMID: 37366663 Abstract Since the worldwide spread of severe acute respiratory syndrome […]
Insurance Industry Execs ‘Alarmed’ by Surge in Deaths Among Young People — But Stop Short of Blaming COVID Shots
According to InsuranceNewsNet, insurers are especially concerned by data from the Centers for Disease Control and Prevention that show “mortality rates alarmingly rising for different categories,” including younger adult mortality […]
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing […]
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial
Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim, MD Jonathan Cohen, MD8; David Kavtaradze, MD9, Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question Does ivermectin, […]
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization
Maxime Taquet, Zuzanna Skorniewska, Adam Hampshire, James D. Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krisnah Poinasamy, Betty Raman, Olivia C. Leavy, Matthew Richardson, Omer Elneima, Hamish J. C. McAuley, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Ruth M. Saunders, Victoria C. Harris, Linzy Houchen-Wolloff, Neil J. Greening, Parisa Mansoori, Ewen M. […]
Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19
Janessa Y.J. Tan,1 Danielle E. Anderson,2,3 Abhay P.S. Rathore,4 Aled O’Neill,1 Chinmay Kumar Mantri,1 Wilfried A.A. Saron,1 Cheryl Q.E. Lee,5 Chu Wern Cui,5 Adrian E.Z. Kang,1 Randy Foo,1 Shirin Kalimuddin,1,6 Jenny G. Low,1,6 Lena Ho,5 Paul Tambyah,7,8 Thomas W. Burke,9 Christopher W. Woods,9,10 Kuan Rong Chan,1 Jörn […]
Simvastatin in Critically Ill Patients with Covid-19
November 2, 2023, NEJM Abstract BACKGROUND The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS In an ongoing international, multifactorial, adaptive platform, randomized, […]
Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
Siriruk Changrob,1 Peter J. Halfmann,2 Hejun Liu,3 Jonathan L. Torres,3 Joshua J.C. McGrath,1 Gabriel Ozorowski,3 Lei Li,1 G. Dewey Wilbanks,1 Makoto Kuroda,2 Tadashi Maemura,2 Min Huang,1 Nai-Ying Zheng,1 Hannah L. Turner,3 Steven A. Erickson,4 Yanbin Fu,1 Atsuhiro Yasuhara,1 Gagandeep Singh,5,6 Brian Monahan,6,7 Jacob Mauldin,6,7 Komal Srivastava,6,7 Viviana Simon,5,6,7,8,9 Florian Krammer,5,6,7 D. Noah […]
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
James May, Jane A. Mitchell, and R. Gisli Jenkins, Published September 15, 2023 – 10.1172/JCI172058 Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with poor survival. The incidence and […]